229 Results for "

Kv

" in MedChemExpress (MCE) Product Catalog:
Products (229)

229 Results for "Kv" in MCE Product Catalog:

22
22 Publications Verification
Cat. No.: HY-N1584
CAS No.: 55837-20-2
Synonyms: RU-19110
Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
loading...
    loading...
22
22 Publications Verification
Cat. No.: HY-N1584C
CAS No.: 82186-71-8
Synonyms: RU-19110 lactate
Halofuginone lactate, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone lactate is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone lactate is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone lactate has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
loading...
    loading...
22
22 Publications Verification
Cat. No.: HY-N1584A
CAS No.: 64924-67-0
Synonyms: RU-19110 hydrobromide
Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
loading...
    loading...
20
20 Cited Publications
Cat. No.: HY-N1584B
CAS No.: 1217623-74-9
Synonyms: RU-19110 hydrochloride
Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-10015
CAS No.: 870653-45-5
Purity:  99.83%
Synonyms: 5-(4-Phenoxybutoxy)psoralen
Target:  

Potassium Channel

Research Areas:  

Inflammation/Immunology

PAP-1 (5-(4-Phenoxybutoxy)psoralen) is a potent, selective, and orally active Kv1.3 blocker (EC50=2 nM). PAP-1 blocks Kv1.3 in a use-dependent manner and acts by preferentially binding to the C-type inactivated state of the channel. PAP-1 exhibits 23-fold selectivity over Kv1.5 (EC50=45 nM), and further displays 33- to 125-fold selectivity over all other Kv1-family channels. PAP-1 does not exhibit cytotoxic or phototoxic effects .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-100912
CAS No.: 61714-27-0
Purity:  99.96%
W-7 hydrochloride is a selective calmodulin antagonist. W-7 hydrochloride inhibits the Ca 2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 hydrochloride induces apoptosis and has antitumor and vascular relaxing activity. W-7 hydrochloride is a blocker of Kv4.3 and can be used for research of arrhythmias .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-130368
CAS No.: 65595-90-6
W-7 is a selective calmodulin antagonist. W-7 inhibits the Ca 2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 induces apoptosis and has antitumor and vascular relaxing activity. W-7 is a blocker of Kv4.3 and can be used for research of arrhythmias .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-50722
CAS No.: 357400-13-6
Synonyms: NNC 55-0396 dihydrochloride
NNC 55-0396 (NNC 55-0396 dihydrochloride) is a blood-brain-barrier-permeable T-type Ca 2+ channel inhibitor and pan-P450 inhibitor. NNC 55-0396 selectively inhibits T-type Ca 2+ channels, suppresses HIF-1α expression and stability and inhibits Kv currents. NNC 55-0396 reduces brain infarct and attenuates neurological dysfunction. NNC 55-0396 inhibits the activity of multiple P450 enzymes. NNC 55-0396 (free base) can be used for the research of brain injury, hypertension, and glioblastoma .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-B0189
CAS No.: 112885-41-3
Synonyms: TAK-370; AS-4370
Mosapride is an orally active gastroenterokinetic compound. Mosapride is a 5HT4 agonist. Mosapride is a CYP inducer. Mosapride has a concentration-dependent inhibitory effect on Kv4.3, and its IC50 value is 15.2 μM. Mosapride can be used in the study of gastrointestinal diseases .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-B0189A
CAS No.: 112885-42-4
Synonyms: TAK-370 citrate; AS-4370 citrate
Mosapride citrate is an orally active gastroenterokinetic compound. Mosapride citrate is a 5HT4 agonist. Mosapride citrate is a CYP inducer. Mosapride citrate has a concentration-dependent inhibitory effect on Kv4.3, and its IC50 value is 15.2 μM. Mosapride citrate can be used in the study of gastrointestinal diseases .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-B0189B
CAS No.: 636582-62-2
Synonyms: TAK-370 citrate dihydrate; AS-4370 citrate dihydrate
Mosapride (TAK-370) citrate dehydrate is a gastroprokinetic agent with 5-hydroxytryptamine4 receptor agonist activity and has been widely used in the research of a variety of gastrointestinal disorders. Mosapride citrate dihydrate potently inhibits Kv4.3 in a concentration-dependent manner with IC50 values of 15.2 μM . Mosapride citrate dihydrateselectively stimulates upper GI motility in vivo .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-103192
CAS No.: 40297-09-4
Purity:  99.82%
Synonyms: RMI12330A
MDL12330A (RMI12330A) is an adenylyl cyclases inhibitor. MDL12330A can inhibit KV channels, increases insulin secretion and Ca 2+ levels. MDL12330A accentuates contractions in uterine rings and inhibits cardiac functions. MDL12330A can be used for the research of endocrinology, metabolic and cardiovascular disease .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-108577
CAS No.: 122955-13-9
Purity:  99.63%
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

XE991 dihydrochloride, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC50s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-108577A
CAS No.: 122955-42-4
Purity:  99.62%
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

XE 991 dihydrochloride, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC50s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-14183
CAS No.: 748810-28-8
Purity:  99.33%
Synonyms: RSD1235 hydrochloride
Target:  

Potassium Channel

Research Areas:  

Cardiovascular Disease

Vernakalant hydrochloride is a mixed voltage- and frequency-dependent Na + and atria-preferred K + channel blocker. IC50 for block by Vernakalant of wild-type and mutant Kv1.5 channels Fractional block is 13.35±0.93 μM, 0.61±0.03 μM, and 1.63±0.09 μM for Kv1.5 channel wt, Kv1.5 channel I508F, Kv1.5 channel T479A, respectively.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-101396
CAS No.: 582323-16-8
Purity:  99.20%
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

ICA-069673 is a KCNQ2/Q3 potassium channel activator. ICA-069673 demonstrates greater selectivity for KV7.2/7.3 over KV7.3/KV7.5, with EC50s of 0.69 μM and 14.3 μM, respectively. ICA-069673 inhibits spontaneous phasic and nerve-evoked contractions in guinea pig detrusor smooth muscle (DSM). ICA-069673 also decreases the global intracellular Ca(2+) concentration in DSM cells .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-120033
CAS No.: 1393441-53-6
Purity:  98.59%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

RY796 is a potent and selective voltage-gated potassium (KV2) channel inhibitor with IC50s of 0.25 μM and 0.09 μM for KV2.1 and KV2.2. RY796 has analgesic activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-W020468
CAS No.: 105431-72-9
Synonyms: DuP 996
Research Areas:  

Neurological Disease

Linopirdine (DuP 996) is an orally active, selective M-type K + current (IM; Kv7; KCNQ Channels) inhibitor with an IC50 of 2.4 μM. Linopirdine is a TRPV1 agonist. Linopirdine, a putative cognition enhancing agent, increases acetylcholine release in rat brain tissue .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-139791
CAS No.: 1009344-33-5
Purity:  99.61%
Synonyms: XEN1101
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

Azetukalner (XEN1101) is a selective and orally active Kv7.2/Kv7.3 potassium channel opener with an EC50 of 27 nM. Azetukalner is approximately 4-fold more selective for Kv7.2/7.3 over Kv7.3/7.5 (EC50 of 94 nM) and Kv7.4 (EC50 of 113 nM) channels. Azetukalner exhibits a selectivity >100-fold for Kv7 channels over other ion channels and receptors. Azetukalner can be used for the study of focal epilepsy .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-100712
CAS No.: 43077-30-1
Purity:  98.39%
DPO-1 is a potent Kv1.5 and Kv1.3 (EC50 = 3.1 μM) channels inhibitor with potential immunomodulatory and anti-inflammatory effects. DPO-1 reduces Kv1.3 current density, blunts Ca 2+ influx in Ca 2+-depleted Jurkat cells, and inhibits IL-2 secretion in activated Jurkat cells. DPO-1 inhibits Uric acid sodium (HY-B2130A) (MSU)-induced NLRP3 inflammasome activation by blocking Kv1.5-mediated K + efflux. DPO-1 can be used for the study of immunologic disorders and atrial fibrillation .
loading...
    loading...